GlassScriptPhysician profile
Jeffrey Brashear
NPI 1962883892
$45,773.21
in general payments reported to CMS, 2019-2025
23 companies · $5,133 in 2025
The $5,133 reported for 2025 was more than what 91% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.43 · 2021: $6,544 · 2022: $670 · 2023: $315 · 2024: $33K · 2025: $5,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $35K · Food and Beverage: $2,151 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Travel and Lodging: $565 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $34,800.00 |
| Food and Beverage | $2,151.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Travel and Lodging | $564.56 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $44,215.53 | 2021-2025 | |
| Davol INC. | $862.07 | 2021-2023 | Phasix Mesh, Ventralight St, Arista Ah Flexitip |
| W. L. Gore & Associates, INC. | $74.76 | 2020-2021 | |
| Medtronic, INC. | $71.38 | 2022 | |
| Smith+Nephew, INC. | $60.32 | 2023-2024 | Collagenase Santyl, Stravix, Regranex |
| Reprise Biomedical, INC. | $56.01 | 2021-2025 | Miro3d |
| Pacira Pharmaceuticals Incorporated | $53.45 | 2025 | Exparel |
| Heron Therapeutics, INC. | $40.34 | 2022-2023 | Aponvie |
| Axonics, INC. | $35.82 | 2023-2024 | Axonics |
| Vertex Pharmaceuticals Incorporated | $34.35 | 2024-2025 | |
| Tela Bio, INC. | $29.66 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $28.03 | 2020-2021 | |
| Acacia Pharma INC | $22.67 | 2022 | |
| Teleflex LLC | $22.38 | 2025 | Titan Sgs Bailout Chuck |
| Astrazeneca Pharmaceuticals LP | $22.00 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $20.17 | 2022 | |
| Ambu INC. | $20.00 | 2023 | |
| Baxter Healthcare | $19.69 | 2021 | |
| La Jolla Pharmaceutical Company | $18.77 | 2023 | Xerava |
| Takeda Pharmaceuticals U.S.A., INC. | $17.46 | 2021 | |
| Bard Peripheral Vascular, INC. | $16.79 | 2023 | Pristine |
| Innocoll Pharmaceuticals Limited | $15.85 | 2022 | |
| Merck Sharp & Dohme LLC | $15.71 | 2024 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Brashear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.